High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS

Clinical Infectious Diseases

Volumn 22, Issue 5, 1996, Pages 838-840

  Menichetti, Francesco ^a   Fiorio, Maurizio ^b   Tosti, Andrea ^b   Gatti, Giorgio ^b   Pasticci, Maria Bruna ^b   Miletich, Franca ^b   Marroni, Massimo ^b   Bassetti, Dante ^b   Pauluzzi, Sergio ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FUNGAL MENINGITIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL;

EID: 0030017192     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.5.838     Document Type: Article

References (12)

1. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
2. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-7.
3. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.
4. Tomberling MG, Baingana G, Grant R, Mbidde EK, Sande MA. Fluconazole with and without flucytosine for AIDS-related cryptococcal meningitis in Uganda [abstract no M 71]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994:247.
5. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36:690-2.
6. Hosotsubo KK, Hosotsubo H, Nishijima MK, Okada T, Taenaka N, Yoshiya I. Rapid determination of serum levels of a new antifungal agent, fiuconazole, by high-performance liquid chromatography. J Chromatogr 1990;529:223-8.
7. Espinel-Ingroff A, Kish CW Jr, Kerkering TM, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992;30:3138-45.
8. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA, the California Collaborative Treatment Group. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis 1994;170:238-42.
9. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72.
10. Morace G, Manzara S, Dettori G. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fiuorocytosine, amphotericin B and ketoconazole. Chemotherapy 1991;37:23-31.
11. Wilt MD, Mortara LA, Larsen RA, Lewis RJ, Edwards JE, Ghannoum MA. In vitro susceptibility of Cryptococcus neoformans predicts failure of primary therapy with fluconazole in patients with cryptococcal meningitis and AIDS [abstract no WS-B12-4]. In: Program and abstracts of the 9th International Conference on AIDS/STD World Congress (Berlin). London: Wellcome Foundation, 1993:93.
12. Van Der Horst C, Saag M, Cloud G, et al. Part 1. Randomized double blind comparison of amphotericin B plus flucytosine (AMB+FC) to AMB alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of acute cryptococcal meningitis in patients with AIDS [abstract no 1216]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:244.